(19)
(11) EP 3 335 728 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.03.2020 Bulletin 2020/11

(45) Mention of the grant of the patent:
25.12.2019 Bulletin 2019/52

(21) Application number: 18150843.3

(22) Date of filing: 13.10.2009
(51) International Patent Classification (IPC): 
A61K 39/21(2006.01)

(54)

BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE

BIOCHEMISCH STABILISIERTER HIV-1-ENV-TRIMER-IMPFSTOFF

VACCIN COMPRENANT UN TRIMÈRE DE ENV DE HIV-1 STABILISÉ BIOCHIMIQUEMENT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 10.10.2008 US 104449 P

(43) Date of publication of application:
20.06.2018 Bulletin 2018/25

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09820044.7 / 2340038

(73) Proprietors:
  • Children's Medical Center Corporation
    Boston, MA 02115 (US)
  • Beth Israel Deaconess Medical Center, Inc.
    Boston, MA 02215 (US)

(72) Inventors:
  • Harrison, Stephen C.
    Brighton, MA 02135 (US)
  • Chen, Bing
    Chestnut Hill, MA 02467 (US)
  • Barouch, Dan H.
    Boston, MA 02215 (US)
  • Nikolola, Joseph P.
    Watertown, MA 02472 (US)
  • Seaman, Michael Scott
    West Roxbury, MA 02132 (US)

(74) Representative: Leonard, Thomas Charles 
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56) References cited: : 
   
  • RODENBURG CYNTHIA M ET AL: "Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 17, no. 2, 20 January 2001 (2001-01-20), pages 161-168, XP002318557, ISSN: 0889-2229, DOI: 10.1089/08892220150217247
  • BOWER JOSEPH F ET AL: "Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.", JOURNAL OF VIROLOGY MAY 2004, vol. 78, no. 9, May 2004 (2004-05), pages 4710-4719, XP002778528, ISSN: 0022-538X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).